| Posted date | Nonproprietary name | Detailed information on revisions of PRECAUTIONS (from MHLW) | Summary of investigation results (from PMDA) |
|---|---|---|---|
| March 30, 2021 | Onasemnogene abeparvovec |  |
|
| February 25, 2021 | Tisagenlecleucel | |
|
Back
Back
-
Regulations & Services of PMDAInformation about Approved Products in JapanInternational ActivitiesSafety InformationAdvanced Efforts
-
Information for approved products in JapanSafety information
-
Development of Drugs, Medical devices, Regenerative medicines and in Vitro diagnosticsInformation for approved products in JapanRegulatory science
-
Regulations and services of PMDAInformation for approved products in JapanProcedures in JapanAdvanced efforts
Back
-
Regulations and Services of PMDAInformation for apporoved products in JapanSafety informationProcedures in Japan
-
Regulations and Services of PMDAInformation for apporoved products in JapanSafety informationProcedures in Japan
-
Reviews and Related ServicesRegulatory ProceduresPost-marketing Safety Measures
-
Reviews and Related ServicesPost-marketing Safety
Measures
- Home
- Post-marketing Safety Measures
- Provision of Information regarding Post-marketing Safety
- Regenerative Medical Products
- Revisions of PRECAUTIONS
- Revisions of PRECAUTIONS (FY2020)
Post-marketing Safety Measures